Low risk of viral infection after administration of vapor-heated factor VIII concentrate

P. M. Mannucci, K. Schimpf, T. Abe, L. M. Aledort, K. Anderle, D. B. Brettler, M. W. Hilgartner, P. B A Kernoff, M. Kunschak, C. W. McMillan, F. E. Preston, G. E. Rivard, W. Muntean, H. Vinazzer, H. Schmitt, C. Durin, Y. Sultin, T. Nagao, J. Mimaya

Research output: Contribution to journalArticlepeer-review


A multicenter prospective study was carried out to evaluate whether a vapor-heated factor VIII concentrate transmitted blood-borne viral infections over a surveillance period of 15 months. Thirty-five patients with hemophilia and von Willebrand disease who had never received any blood components were treated. Twenty-eight were analyzed and found not to have non-A, non-B hepatitis. Sera from 20 of these 28 patients were also tested for the antibody to the hepatitis C virus. None had sero-converted during the follow- up period. None of the patients analyzed developed markers of the hepatitis B virus (n = 17) or the human immunodeficiency virus (n = 31). This vapor- heated factor VIII concentrate carries a low risk of transmitting hepatitis and human immunodeficiency virus infection.

Original languageEnglish
Pages (from-to)134-138
Number of pages5
Issue number2
Publication statusPublished - 1992

ASJC Scopus subject areas

  • Immunology
  • Hematology


Dive into the research topics of 'Low risk of viral infection after administration of vapor-heated factor VIII concentrate'. Together they form a unique fingerprint.

Cite this